|
Component / Product |
Composition |
Volume |
Indications |
|
Whole Blood |
RBCs
(approx. Hct 40%); plasma;
WBCs;
plts |
500
mL |
Increase both red cell
mass and plasma volume (WBCs and
plts not functional; plasma deficient in
labile clotting Factors V and VIII) |
|
Red Blood Cells |
RBC (approx.
Hct 75%); reduced plasma,
WBCs, and
plts |
250 m L |
Increase red cell mass in
symptomatic anemia (WBCs and
plts not functional) |
|
Red Blood Cells,
Adenine-Saline Added |
RBC (approx.
Hct 60%); reduced plasma,
WBCs, and plts;
100 mL of additive solution |
330
mL |
Increase red cell mass in
symptomatic anemia (WBCs and
plts not functional) |
|
RBC’s
Leukocytes Reduced (prepared by filtration |
>85% original volume of
RBC; <5 x 106 WBC; few plts;
minimal plasma |
225
mL |
Increase red cell mass; <5
x 106 WBCs to decrease the
likelihood of febrile reactions, immunization to leukocytes (HLA
antigens) or CMV transmission |
|
RBCs
Washed |
RBCs
(approx. Hct 75%); <5 x 108
WBCs; no plasma |
180
mL |
Increase red cell mass;
reduce risk of allergic reactions to plasma proteins |
|
RBCs
Frozen; RBCs Deglycerolized |
RBC (approx.
Hct 75%); <5 x 108
WBCs; no plts;
no plasma |
180
mL |
increase red cell mass;
minimize febrile or allergic transfusion reactions; use for
prolonged RBC blood storage |
|
Granulocytes
Pheresis |
Granulocytes (>1.0 x 1010
PMN/unit); lymphocytes; plts (>2.0
x 1011/unit); some RBCs |
220 m L |
Provide granulocytes for
selected patients with sepsis and severe
neutropenia (<500 PMN/µL) |
|
Platelets |
Plts
(>5.5 x 1010/unit); RBC; WBCs;
plasma |
50 m L |
Bleeding due to
thrombocytopenia or
thrombocytopathy |
|
Platelets
Pheresis |
Plts
(>3 x 1011/unit); RBCs,
WBCs, plasma |
300
mL |
Same as
plts; sometimes HLA matched |
|
Platelets Leukocytes
Reduced |
Plts
(as above); <5 x 106 WBCs per final dose
of pooled plts |
300 m L |
Same as
plts; <5 x 106 WBCs
to decrease the likelihood of febrile reactions,
alloimmunization to leukocytes (HLA
antigens or CMV transmission |
|
FFP; DR‑P; SD‑P |
Plasma; all coagulation
factors; complement (no plts) |
220 m L |
Treatment of some
coagulation disorders |
|
Cryoprecipitated
AHF |
Fibrinogen; Factors VIII
and XIII; von Willebrand factor |
15
mL |
Deficiency of fibrinogen;
Factor XIII; second choice in treatment of Hemophilia A, von
Willebrand's disease |
|
Factor VI I
I (concentrates, recombinant human
Factor VIII) |
Factor VI II; trace amount
of other plasma proteins (products vary in purity) |
25 m L |
Hemophilia A (Factor VIII
deficiency); von Willebrand's disease
(off‑label use for selectec products
only) |
|
Factor IX (concentrates,
recombinant human Factor IX) |
Factor IX; trace amount of
other plasma proteins (products vary in purity) |
25 m L |
Hemophilia B (Factor IX
deficiency) |
|
Albumin/PPF |
Albumin, some a‑,
p‑globulins |
(5%); (25%) |
Volume expansion |
|
Immune Globulin |
IgG
antibodies; preparations for IV and/or IM use |
varies |
Treatment of hypo‑ or
agammaglobulinemia; disease prophylaxis;
autoimmune thrombocytopenia (IV only) |
|
Rh
Immune Globulin |
IgG
anti‑D; preparations for IV and/or IM use |
1
mL |
Prevention of hemolytic
disease of the newborn due to D antigen; treatment of autoimmune
thrombocytopenia |
